Search Results within category "Diabetes, Metabolism & Hormones"
Search all categoriesSuggestions within category "Diabetes, Metabolism & Hormones"
6
Study Matches
CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients
This is a Phase II/III, Single-center, Prospective, Open-label, Single Arm Study of 30
Simultaneous Kidney Pancreas recipients who received a transplant at least 3 months, but no
more than 5 years prior, with a history of tremors following transplantation.
Jon Odorico, MD
All
18 Years to 70 Years old
Phase 2/Phase 3
NCT03769298
Kidney Pancreas Transplantation, Complications of kidney transplant, Other, Transplant, Diabetes, Metabolism & Hormones
Antecedent Metabolic Health and Metformin Aging Study (ANTHEM)
Aging is the number one risk factor for the majority of chronic diseases. There are no
pharmaceutical treatments to slow aging and prolong healthspan. The anti-diabetic drug
metformin is considered a likely pharmaceutical candidate to slow aging. In this study, the
investigators hypothesize that metformin treatment in subjects free of type 2 diabetes will
improve insulin sensitivity and glucoregulation in insulin resistant individuals, but will
decrease insulin sensitivity and glucoregulation in insulin sensitive subjects. Further, the
investigators hypothesize that long-term metformin treatment will remodel mitochondria in a
way that decreases mitochondrial function in subjects that are insulin sensitive, but
improves mitochondrial function in subjects that are insulin resistant. The investigators
will use a dual-site, 12- week drug intervention trial performed in a double-blind,
placebo-controlled manner on 148 subjects recruited from two separate sites (Oklahoma Medical
Research Foundation (OMRF) and University of Wisconsin-Madison (UWM)). After consent and
initial subject screening for chronic disease, subjects will be stratified to insulin
sensitive (IS) or insulin resistant (IR) groups. Over a 12- week intervention, half of each
group will take metformin and half will take a placebo. Pre- and post--intervention, subjects
will complete a series of procedures to assess insulin sensitivity, glucose regulation, and
biomarkers of aging. The same subjects will provide a skeletal muscle biopsy pre-- and
post-intervention to assess the change in mitochondrial function and mitochondrial remodeling
with and without metformin treatment. By completion of this project, the investigators expect
to provide evidence that helps further delineate who may benefit from metformin treatment to
slow aging.
Adam Konopka
All
40 Years to 75 Years old
Phase 3
NCT04264897
Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance, Healthy Volunteers, Other, Aging & Geriatrics
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in
participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH)
and severe hypoglycemia.
Jon Odorico, MD
All
18 Years to 65 Years old
Phase 1/Phase 2
NCT04786262
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia, Other specified diabetes mellitus, Other, Transplant
AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy
This study will assess differences in patient preferences and glucose control between
continuous glucose monitoring and standard glucose checks in pregnant patients with Type 2
Diabetes. 40 participants will be on study for approximately 182 days (26 weeks).
Jacquelyn Adams
Female
18 Years to 45 Years old
N/A
NCT05370612
Type2Diabetes, Pregnancy in Diabetic, Other
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to
evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue
from patients with and without cancer to study in the laboratory may help researchers develop
tests for the early detection of cancers.
David Kosoff, MD
All
40 Years to 75 Years old
N/A
NCT05334069
Lip, Oral Cavity and Pharynx, Esophagus, Stomach, Small Intestine, Colon, Rectum, Anus, Liver, Pancreas, Other Digestive Organ, Larynx, Lung, Other Respiratory and Intrathoracic Organs, Bones and Joints, Soft Tissue, Melanoma, Skin, Kaposi's Sarcoma, Mycosis Fungoides, Other Skin, Breast, Cervix, Corpus Uteri, Ovary, Other Female Genital, Prostate, Other Male Genital, Urinary Bladder, Kidney, Other Urinary, Eye and Orbit, Brain and Nervous System, Thyroid, Other Endocrine System, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Leukemia, other, Other Hematopoietic, Unknown Sites, Ill-Defined Sites, Any Site, Anal, Bladder, Brain/Central Nervous System, Colon and Rectum, Endocrine cancers, Gastrointestinal cancers, other, Genitourinary cancers, other, Head and Neck, Hematologic cancers, other, Leukemia, Lymphoma, Melanoma/Skin cancer, Uterus, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Everolimus Aging Study (EVERLAST)
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5
mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular
hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or
prediabetic will be randomized to treatment and can expect to be on study for up to
approximately 38 weeks. Participants aged 18-35 will not receive the intervention and can
expect to be on study for up to approximately 8 weeks.
Adam Konopka
All
18 Years to 80 Years old
Phase 2
NCT05835999
Aging, Insulin Resistance, Other